110
K. Kawakami
7. Blaabjerg, L.I., Lindenberg, E., Löbmann, K., Grohganz, H., Rades, T.: Glass forming ability
of amorphous drugs investigated by continuous cooling and isothermal transformation. Mol.
Pharm. 13, 3318–3325 (2016)
8. Kawakami, K.: Supersaturation and crystallization: non-equilibrium dynamics of amorphous
solid dispersions for oral drug delivery. Expert Opin. Drug Deliv. 14, 735–743 (2017)
9. Kawakami, K., Harada, T., Miura, K., Yoshihashi, Y., Yonemochi, E., Terada, K., Moriyama,
H.: Relationship between crystallization tendencies during cooling from melt and isothermal
storage: toward a general understanding of physical stability of pharmaceutical glasses. Mol.
Pharm. 11, 1835–1843 (2014)
10. Kawakami, K., Ohba, C.: Crystallization of probucol from solution and the glassy state. Int. J.
Pharm. 517, 322–328 (2017)
11. Kawakami, K.: Surface effects on the crystallization of ritonavir glass. J. Pharm. Sci. 104,
276–279 (2015)
12. Kawakami, K.: Ultraslow cooling for the stabilization of pharmaceutical glasses. J. Phys. Chem.
B 123, 4996–5003 (2019)
13. Angell, C.A.: Relaxation in liquids, polymers and plastic crystals—strong/fragile patterns and
problems. J. Non-Cryst. Solids 131–133, 13–31 (1991)
14. Crowley, K.J., Zografi, G.: The use of thermal methods for predicting glass-former ability.
Thermochim. Acta 380, 79–93 (2001)
15. Kawakami, K., Harada, T., Yoshihashi, Y., Yonemochi, E., Terada, K., Moriyama, H.: Correlation between glass forming ability and fragility of pharmaceutical compounds. J. Phys. Chem.
B 119, 4873–4880 (2015)
16. Bauer, J., Spanton, S., Henry, R., Quick, J., Dziki, W., Porter, W., Morris, J.: Ritonavir: an
extraordinary example of conformational polymorphism. Pharm. Res. 18, 859–866 (2001)
17. Tominaka, S., Kawakami, K., Fukushima, M., Miyazaki, A.: Physical stabilization of pharmaceutical glasses based on hydrogen bond reorganization under sub-Tg temperature. Mol.
Pharm. 14, 264–273 (2017)
18. Kawakami, K.: Nucleation and crystallization of celecoxib glass: impact of experience of low
temperature on physical stability. Thermochim. Acta 671, 43–47 (2019)
19. Descamps, M., Dudognon, E.: Crystallization from the amorphous state: nucleation-growth
decoupling, polymorphism interplay, and the role of interfaces. J. Pharm. Sci. 103, 2615–2628
(2014)
20. Bhugra, C., Shmeis, R., Pikal, M.J.: Role of mechanical stress in crystallization and relaxation
behavior of amorphous indomethacin. J. Pharm. Sci. 97, 4446–4458 (2008)
21. Kawakami, K., Miyoshi, K., Tamura, N., Yamaguchi, T., Ida, Y.: Crystallization of sucrose
glass under ambient conditions: evaluation of crystallization rate and unusual melting behavior
of resultant crystals. J. Pharm. Sci. 95, 1354–1363 (2006)
22. Ayenew, Z., Paudel, A., Rombaut, P., Van den Mooter, G.: Effect of compression on nonisothermal crystallization behaviour of amorphous indomethacin. Pharm. Res. 29, 2489–2498
(2012)
23. Rams-Baron, M., Pacult, J., Jedrzejowska, A., Knapik-Kowalczuk, J., Paluch, M.: Changes in
physical stability of supercooled etoricoxib after compression. Mol. Pharm. 15, 2969–3978
(2018)
24. Crowley, K.J., Zografi, G.: Cryogenic grinding of indomethacin polymorphs and solvates:
assessment of amorphous phase formation and amorphous phase physical stability. J. Pharm.
Sci. 91, 492–507 (2002)
25. Otsuka, M., Kaneniwa, N.: A kinetic study of the crystallization process of noncrystalline
indomethacin under isothermal conditions. Chem. Pharm. Bull. 36, 4026–4032 (1988)
26. Andronis, V., Zografi, G.: Crystal nucleation and growth of indomethacin polymorphs from
the amorphous state. J. Non-Cryst. Solids 271, 236–248 (2000)
27. Bhugra, C., Shmeis, R., Krill, S.L., Pikal, M.J.: Prediction of onset of crystallization from
experimental relaxation times. II. Comparison between predicted and experimental onset times.
J. Pharm. Sci. 97, 455–472 (2008)
K. Kawakami
7. Blaabjerg, L.I., Lindenberg, E., Löbmann, K., Grohganz, H., Rades, T.: Glass forming ability
of amorphous drugs investigated by continuous cooling and isothermal transformation. Mol.
Pharm. 13, 3318–3325 (2016)
8. Kawakami, K.: Supersaturation and crystallization: non-equilibrium dynamics of amorphous
solid dispersions for oral drug delivery. Expert Opin. Drug Deliv. 14, 735–743 (2017)
9. Kawakami, K., Harada, T., Miura, K., Yoshihashi, Y., Yonemochi, E., Terada, K., Moriyama,
H.: Relationship between crystallization tendencies during cooling from melt and isothermal
storage: toward a general understanding of physical stability of pharmaceutical glasses. Mol.
Pharm. 11, 1835–1843 (2014)
10. Kawakami, K., Ohba, C.: Crystallization of probucol from solution and the glassy state. Int. J.
Pharm. 517, 322–328 (2017)
11. Kawakami, K.: Surface effects on the crystallization of ritonavir glass. J. Pharm. Sci. 104,
276–279 (2015)
12. Kawakami, K.: Ultraslow cooling for the stabilization of pharmaceutical glasses. J. Phys. Chem.
B 123, 4996–5003 (2019)
13. Angell, C.A.: Relaxation in liquids, polymers and plastic crystals—strong/fragile patterns and
problems. J. Non-Cryst. Solids 131–133, 13–31 (1991)
14. Crowley, K.J., Zografi, G.: The use of thermal methods for predicting glass-former ability.
Thermochim. Acta 380, 79–93 (2001)
15. Kawakami, K., Harada, T., Yoshihashi, Y., Yonemochi, E., Terada, K., Moriyama, H.: Correlation between glass forming ability and fragility of pharmaceutical compounds. J. Phys. Chem.
B 119, 4873–4880 (2015)
16. Bauer, J., Spanton, S., Henry, R., Quick, J., Dziki, W., Porter, W., Morris, J.: Ritonavir: an
extraordinary example of conformational polymorphism. Pharm. Res. 18, 859–866 (2001)
17. Tominaka, S., Kawakami, K., Fukushima, M., Miyazaki, A.: Physical stabilization of pharmaceutical glasses based on hydrogen bond reorganization under sub-Tg temperature. Mol.
Pharm. 14, 264–273 (2017)
18. Kawakami, K.: Nucleation and crystallization of celecoxib glass: impact of experience of low
temperature on physical stability. Thermochim. Acta 671, 43–47 (2019)
19. Descamps, M., Dudognon, E.: Crystallization from the amorphous state: nucleation-growth
decoupling, polymorphism interplay, and the role of interfaces. J. Pharm. Sci. 103, 2615–2628
(2014)
20. Bhugra, C., Shmeis, R., Pikal, M.J.: Role of mechanical stress in crystallization and relaxation
behavior of amorphous indomethacin. J. Pharm. Sci. 97, 4446–4458 (2008)
21. Kawakami, K., Miyoshi, K., Tamura, N., Yamaguchi, T., Ida, Y.: Crystallization of sucrose
glass under ambient conditions: evaluation of crystallization rate and unusual melting behavior
of resultant crystals. J. Pharm. Sci. 95, 1354–1363 (2006)
22. Ayenew, Z., Paudel, A., Rombaut, P., Van den Mooter, G.: Effect of compression on nonisothermal crystallization behaviour of amorphous indomethacin. Pharm. Res. 29, 2489–2498
(2012)
23. Rams-Baron, M., Pacult, J., Jedrzejowska, A., Knapik-Kowalczuk, J., Paluch, M.: Changes in
physical stability of supercooled etoricoxib after compression. Mol. Pharm. 15, 2969–3978
(2018)
24. Crowley, K.J., Zografi, G.: Cryogenic grinding of indomethacin polymorphs and solvates:
assessment of amorphous phase formation and amorphous phase physical stability. J. Pharm.
Sci. 91, 492–507 (2002)
25. Otsuka, M., Kaneniwa, N.: A kinetic study of the crystallization process of noncrystalline
indomethacin under isothermal conditions. Chem. Pharm. Bull. 36, 4026–4032 (1988)
26. Andronis, V., Zografi, G.: Crystal nucleation and growth of indomethacin polymorphs from
the amorphous state. J. Non-Cryst. Solids 271, 236–248 (2000)
27. Bhugra, C., Shmeis, R., Krill, S.L., Pikal, M.J.: Prediction of onset of crystallization from
experimental relaxation times. II. Comparison between predicted and experimental onset times.
J. Pharm. Sci. 97, 455–472 (2008)